European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients

• Published in: Cancer science Vol. 105; no. 1; pp. 105 - 109
• Main Authors: Yamamoto, Eri, Fujisawa, Shin, Hagihara, Maki, Tanaka, Masatsugu, Fujimaki, Katsumichi, Kishimoto, Kumiko, Hashimoto, Chizuko, Itabashi, Megumi, Ishibashi, Daisuke, Nakajima, Yuki, Tachibana, Takayoshi, Kawasaki, Rika, Kuwabara, Hideyuki, Koharazawa, Hideyuki, Yamazaki, Etsuko, Tomita, Naoto, Sakai, Rika, Fujita, Hiroyuki, Kanamori, Heiwa, Ishigatsubo, Yoshiaki
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.01.2014; BlackWell Publishing Ltd
• Subjects: Adolescent; Adult; Age; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Benzamides - therapeutic use; Blood platelets; Chemotherapy; Chronic myeloid leukemia; Cytogenetics; Disease-Free Survival; European Treatment and Outcome Study score; Female; Hasford score; Hematology; Humans; Imatinib; Imatinib Mesylate; Interferon; Leukemia; Leukemia, Myeloid, Chronic-Phase - drug therapy; Leukemia, Myeloid, Chronic-Phase - pathology; Male; Medical prognosis; Middle Aged; Myeloid leukemia; Original; Outcome Assessment (Health Care) - methods; Piperazines - therapeutic use; Prognosis; Pyrimidines - therapeutic use; Retrospective Studies; Risk groups; Sokal score; Spleen; Survival; Survival Rate; Treatment Outcome; validation; Young Adult; Chronic myeloid leukemia; Sokal score; European Treatment and Outcome Study score; validation; Hasford score
• ISSN: 1347-9032; 1349-7006; 1349-7006
• DOI: 10.1111/cas.12321

The Sokal and Hasford scores were developed in the chemotherapy and interferon era and are widely used as prognostic indicators in patients with chronic myeloid leukemia (CML). Recently, a new European Treatment and Outcome Study (EUTOS) scoring system was developed. We performed a multicenter retrospective study to validate the effectiveness of each of the three scoring systems. The study cohort included 145 patients diagnosed with CML in chronic phase who were treated with imatinib. In the EUTOS low‐ and high‐risk groups, the cumulative incidence of complete cytogenetic response (CCyR) at 18 months was 86.9% and 87.5% (P = 0.797) and the 5‐year overall survival rate was 92.6% and 93.3% (P = 0.871), respectively. The cumulative incidence of CCyR at 12 months, 5‐year event‐free survival and 5‐year progression‐free survival were not predicted using the EUTOS scoring system. However, there were significant differences in both the Sokal score and Hasford score risk groups. In our retrospective validation study, the EUTOS score did not predict the prognosis of patients with CML in chronic phase treated with imatinib. The EUTOS score did not predict the outcome of the newly diagnosed CML‐CP patients treated with imatinib. However, there were significant differences in both the Sokal score and Hasford score risk groups.